Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration

ConclusionIn clinical settings, aflibercept treatment using a TAE regimen may successfully maintain visual acuity for up to 4  years even in recurrent cases of AMD.
Source: Japanese Journal of Ophthalmology - Category: Opthalmology Source Type: research